Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US9610327B2 · kind B2 · utility
8Cited by
62References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 19, 2012 |
| Grant date | Apr 4, 2017 |
| Priority date | — |
| Expiry date | Dec 19, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/71
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.